A randomized trial of 2 months of rifampin and pyrazinamide vs. 6 months of isoniazid for the treatment of latent tuberculosis infection in HIV negative patients

被引：0
|
作者：
King, MD
Abdulrahman, S
Oladele, A
Tapia, JR
Stringer, E
Blumberg, HM
机构：
[1] Emory Univ, Sch Med, Atlanta, GA USA
[2] DeKalb Cty Board Hlth, Decatur, GA USA
[3] Morehouse Sch Med, Atlanta, GA 30310 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2001年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
341
引用
收藏
页码：1146 / 1146
页数：1
相关论文
共 50 条
  • [1] Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis
    Stout, JE
    Engemann, JJ
    Cheng, AC
    Fortenberry, ER
    Hamilton, CD
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (06) : 824 - 827
  • [2] Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months
    Nolan, CM
    Goldberg, SV
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2002, 6 (11) : 952 - 958
  • [3] Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection
    Pina, Jose Ma
    Clotet, Laura
    Ferrer, Anna
    Rosa Sala, Maria
    Garrido, Patricio
    Salleras, Lluis
    Dominguez, Angela
    [J]. RESPIRATORY MEDICINE, 2013, 107 (05) : 768 - 777
  • [4] Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
    McClintock, Adelaide H.
    Eastment, McKenna
    McKinney, Christy M.
    Pitney, Caroline L.
    Narita, Masahiro
    Park, David R.
    Dhanireddy, Shireesha
    Molnar, Alexandra
    [J]. BMC INFECTIOUS DISEASES, 2017, 17
  • [5] Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
    Adelaide H. McClintock
    McKenna Eastment
    Christy M. McKinney
    Caroline L. Pitney
    Masahiro Narita
    David R. Park
    Shireesha Dhanireddy
    Alexandra Molnar
    [J]. BMC Infectious Diseases, 17
  • [6] Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection
    Menzies, Dick
    Long, Richard
    Trajman, Anete
    Dion, Marie-Josee
    Yang, Jae
    Al Jahdali, Hamdan
    Memish, Ziad
    Khan, Kamran
    Gardam, Michael
    Hoeppner, Vernon
    Benedetti, Andrea
    Schwartzman, Kevin
    [J]. ANNALS OF INTERNAL MEDICINE, 2008, 149 (10) : 689 - U4
  • [7] Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons - An international randomized trial
    Gordin, F
    Chaisson, RE
    Matts, JP
    Miller, C
    Garcia, MD
    Hafner, R
    Valdespino, JL
    Coberly, J
    Schechter, M
    Klukowicz, AJ
    Barry, MA
    O'Brien, RJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (11): : 1445 - 1450
  • [8] Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong kong
    Leung, CC
    Law, WS
    Chang, KC
    Tam, CM
    Yew, WW
    Chan, CK
    Wong, MY
    [J]. CHEST, 2003, 124 (06) : 2112 - 2118
  • [9] Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection
    J. M. Pina
    L. Clotet
    A. Ferrer
    M. R. Sala
    P. Garrido
    L. Salleras
    A. Domínguez
    [J]. European Journal of Clinical Microbiology & Infectious Diseases, 2013, 32 : 647 - 655
  • [10] Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection
    Pina, J. M.
    Clotet, L.
    Ferrer, A.
    Sala, M. R.
    Garrido, P.
    Salleras, L.
    Dominguez, A.
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2013, 32 (05) : 647 - 655
12345